Pembrolizumab Combo Yields Survival Benefit in Endometrial Cancer.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 5, p. 204
- Publication type:
- Article
Works matching IS 08909091 AND DT 2024 AND VI 38 AND IP 5
Results: 11
1
2
Exploring the Benefits and Risks of AI in Oncology.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 5, p. 214
- By:
- Publication type:
- Article
3
Complementary and Alternative Medicine in Cancer Care: Does It Have a Role?
- Published in:
- Oncology (08909091), 2024, v. 38, n. 5, p. 175
- By:
- Publication type:
- Article
4
AI Use in Prostate Cancer: Potential Improvements in Treatments and Patient Care.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 5, p. 212
- By:
- Publication type:
- Article
5
Lenvatinib Combo Prolongs OS, PFS in Advanced Endometrial Cancer Subgroups.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 5, p. 205
- Publication type:
- Article
6
Society of Gynecologic Oncology Annual Meeting on Women's Cancer.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 5, p. 203
- Publication type:
- Article
7
Enfortumab Vedotin Plus Pembrolizumab.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 5, p. 201
- By:
- Publication type:
- Article
8
Forging a Path in Thoracic Surgery to Create a Stellar Career.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 5, p. 196
- By:
- Publication type:
- Article
9
Synchronous Well-Differentiated Papillary Mesothelioma and Endometrioid Adenocarcinoma Arising From Endometriosis.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 5, p. 191, doi. 10.46883/2024.25921020
- By:
- Publication type:
- Article
10
Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT Trial.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 5, p. 187, doi. 10.46883/2024.25921019
- By:
- Publication type:
- Article
11
Our Board Members Have Been Busy! Take a look to see what they've been up to.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 5, p. 172
- Publication type:
- Article